Federal antitrust suit claims two pharmacy benefits managers worked together to suppress pharmacy reimbursements rates, fueling ongoing scrutiny of PBM practices.
Pharmacy Benefit Managers
Industry association group argues the state’s Prescription Drug Affordability Act imposes unconstitutional “mandates” on PBMs that manage prescription benefits for employer-sponsored health plans.
Just in time for midterm elections, a new RFI seeks public input on Medicare drug pricing negotiations, inflation-based rebates, and supply-chain oversight.
If successful, states may face limits on their ability to restrict PBM ownership structures; however, a loss could reshape the pharmacy landscape nationwide.
The pharmacy benefits manager has copped to artificially inflating the list price of drugs by using unfair rebating practices.